Uganda Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2356117
  • December 2012
  • Region: Uganda
  • 39 pages
  • Business Monitor International
1 of 3

BMI View: While geographic diversification and investment into the pharmaceutical and healthcare sector of emerging economies such as Uganda may be a favourable strategy for any multinational pharmaceutical company - it is vital that a company recognises both the rewards and the risks present in a market. With regards to assessing risks in the Ugandan healthcare sector, we have identified industry specific dangers (such as low per-capita spending and poor access to healthcare facilities) and those emanating from the state's political/economic profile (such as high inflation) that call into question the likelihood of anticipated returns being realised over the assessed time period.

Headline Expenditure Projections:

- Pharmaceuticals: UGX676bn (US$268mn) in 2011 to UGX794bn (US$322mn) in 2012;
+14.8% growth in local currency terms and +17.3% in US dollar terms.

- Healthcare: UGX3,942bn (US$1.56bn) in 2011 to UGX4,519bn (US$1.83bn) in 2012; 14.6
%growth in local currency terms and 17.1% in US dollar terms.

Risk/Reward Ratings:

In BMI's Q113 BERs, Uganda is ranked 24th in the Middle East and Africa
(MEA) region. While factors such as population READ MORE >

Note: Product cover images may vary from those shown
2 of 3

Executive Summary 5

Pharmaceutical Risk/Reward Ratings 7
Table: MEA Pharmaceuticals And Healthcare Risk/Reward Ratings, Q113 7

Rewards 9

Risks 9

Market Summary 10

Regulatory Regime 12

Intellectual Property Issues 12

Healthcare Provision 12

Epidemiology 15

Industry Forecast Scenario 17

Pharmaceutical Market Forecast 17
Table: Pharmaceutical Sales Indicators 2008-2016 18

Healthcare Market Forecast 19
Table: Healthcare Expenditure Indicators 2008-2016 22
Table: Healthcare Governmental Indicators 2008-2016 22
Table: Healthcare Private Indicators 2008-2016 23

Macroeconomic Outlook 24
Table: A Rough Fiscal Year 28
Table: Uganda - Economic Activity 28

Demographic Outlook 29
Table: Uganda's Population By Age Group, 1990-2020 ('000) 30
Table: Uganda's Population By Age Group, 1990-2020 (% of total) 31
Table: Uganda's Key Population Ratios, 1990-2020 32
Table: Uganda's Rural And Urban Population, 1990-2020 32

Glossary 33

BMI Methodology 35

How We Generate Our Pharmaceutical Industry Forecasts 35

Pharmaceuticals Risk/Reward Ratings Methodology 36

Ratings Overview 36
Table: Pharmaceutical Business Environment Indicators 37

Weighting 38
Table: Weighting Of Components 38

Sources 38

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.